Abstract:Abstract Background: Gremlin-1 (GREM1), a member of the TGF-β superfamily, plays a key role in EMT, and cancer cell proliferation by binding to BMPs. GREM1 is widely expressed in various human cancers and TME stromal cells. Overexpression of GREM1 is correlated with poor prognosis. TST003 is a novel humanized IgG1 monoclonal antibody targeting GREM1 with high affinity and selectivity, and it blocks GREM1 binding to BMP2/4 resulting in enhanced BMP signaling. This study will investigate TST003’s safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors. Objectives: The primary objectives are to evaluate the safety and tolerability and determine the maximum tolerated dose and/or optimal biologic dose(s) of TST003. Secondary objectives include pharmacokinetic, pharmacodynamic and preliminary anti-tumor activity of TST003. A comprehensive biomarker plan will be implemented to analyze GREM1 expression, BMP signaling pathway, and tumor microenvironment with tumor tissues (including tumor cells, CAFs, Teff, Treg, MDSCs and TAMs), as well as circulating tumor DNA to explore the correlation among drug exposure, pharmacodynamic markers and clinical outcomes. Method: This is a first in human Phase 1 study in locally advanced or metastatic solid tumor subjects having tumor progression during or after prior therapies and have no standard therapy that could confer clinical benefit. It comprises of the Part 1 Dose Escalation and the Part 2 Pharmacodynamic Cohorts. Part 1 will evaluate sequential dose levels of 1, 3, 10, 20 and 30 mg/kg TST003 iv., every three weeks as a single agent. The traditional “3+3” design were used for dose escalation of the first two cohorts (1 and 3 mg/kg), and Bayesian Optimal Interval (BOIN) Design with prespecified cohort size of 3 is used in the following cohorts. Part 2 will include 2 pharmacodynamic cohorts to evaluate the pharmacokinetic (PK) profile, pharmacodynamic (PD) markers, preliminary tumor response, as well as safety of TST003 as monotherapy in locally advanced or metastatic colorectal adenocarcinoma (CRC) subjects. The 2 doses used in the pharmacodynamic cohorts will be chosen from Part 1 and are expected to be within the pharmacologically active range based on nonclinical PK/PD modeling and available clinical PK/PD data from the ongoing study. Baseline GREM1 expression will be analyzed by immunohistochemistry. In each pharmacodynamic cohort, around 13-18 subjects will be enrolled to ensure at least 7 GREM1 positive subjects. Eligible subjects will receive TST003 until unacceptable toxicity or disease progression by RECIST v1.1. The enrollment is ongoing in clinical centers in the US and China. No significant safety signals were reported in the first few patients treated with TST003. Clinical Trial Information: NCT05731271. Study Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. Citation Format: Ismael Rodriguez Rivera, Lin Shen, Shivaani Kummar, Minal Barve, Caroline Germa, Chuan Qi, Lei Chen, Jenny Milata, Jenny Yao, Li Shen, Xuelian Zhu. A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5977.

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).

TREM1 activation of myeloid cells promotes antitumor immunity

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation.

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

A Phase II, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (Anti-Pd-1 Mab) in Patients with Unresectable/metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.

A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study

Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.

The rationale of reprogramming TREM2+ macrophages for overcoming the resistance to immune checkpoint inhibitors in pancreatic adenocarcinoma.

First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET -altered solid tumors

Abstract 6530: TREM1 inhibition: A novel approach to suppress tumor growth and enhance immune checkpoint therapy

Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.

A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.

Abstract 5977: A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors